The related factors of meibomian gland morphological changes

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200063367

Enrollment

Unknown

Registered

2022-09-05

Start date

2022-09-05

Completion date

Unknown

Last updated

2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry eye

Interventions

dry eye group:no

normal group:no

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 18~75 years old patients with dry eye and normal people

Exclusion criteria

Exclusion criteria: Patients with psychosis, cognitive dysfunction, cardio-cerebrovascular accident, malignant arrhythmia, and dysfunction of important organs. Systemic connective tissue diseases and serious autoimmune diseases, such as rheumatoid arthritis, sarcoidosis, lupus erythematosus, thyroiditis, etc. Patients with a history of systemic or ocular surgery, trauma or other diseases requiring long-term use of eye drops

Design outcomes

Primary

Measure	Time frame
Meibomian gland morphology;	—

Secondary

Measure	Time frame
Cornea Fluorescein Staining;demodex infestion;	—

Countries

China

Contacts

Public ContactYana Fu

Eye Hospital and School of Ophthalmology and Optometry Wenzhou Medical University

y_xinxin2018@163.com+86 13003656118

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026